# Ultragenyx Pharmaceutical Inc.

Type: Company (RARE)

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/ultragenyx-pharmaceutical-inc
Canonical HTML page: https://getlegalbrief.com/entity/ultragenyx-pharmaceutical-inc

## Timeline

- **2026-Q3**: Lead Counsel Appointment — Expected timeframe for the court to designate the lead plaintiff and legal representation.
- **2026-05-11**: Lead Plaintiff Deadline — Final day for affected investors to petition the court to lead the class action.
- **2026-04-15**: Lead Plaintiff Deadline — Estimated deadline for investors to file motions to be appointed as lead plaintiff in the respective cases.
- **2026-03-12**: Lawsuit Announcements — Schall Law Firm files class action notices for Soleno Therapeutics and Ultragenyx Pharmaceutical.
- **2026-03-06**: Market Reaction — Investors and analysts begin assessing the potential litigation overhang on RARE, MREO, FRMI, and NAVN.
- **2026-03-05**: Investor Alerts Issued — Pomerantz Law Firm releases simultaneous reminders for class action lawsuits against four companies.

## Recent coverage (2 stories)

### Schall Law Firm Targets Soleno and Ultragenyx in Dual Securities Fraud Actions
2026-03-12 10:04:00 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Schall Law Firm has initiated securities fraud class actions against Soleno Therapeutics and Ultragenyx Pharmaceutical, alleging violations of federal securities laws. The firm is currently seeking lead plaintiffs to represent the class in these high-stakes biotech litigations following potential misrepresentations to the market.
Full story: https://getlegalbrief.com/story/schall-law-firm-soleno-ultragenyx-securities-fraud

### Pomerantz Law Firm Targets Biotech and Tech Sectors in Securities Class Actions
2026-03-05 23:21:10 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Pomerantz Law Firm has issued a series of investor alerts regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These filings highlight a surge in securities litigation targeting volatility in the biotechnology and emerging technology sectors, emphasizing critical lead plaintiff deadlines for affected shareholders.
Full story: https://getlegalbrief.com/story/pomerantz-securities-class-actions-biotech-tech-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.